Skip to main content

Table 2 Changes in antibody responses against P. falciparum antigens in the Papua New Guinean cohort during the course of pregnancy

From: Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission

Variable (n) SP + CQ control arm (n = 304) SP + AZ intervention arm (n = 277) P value
IgG to schizont extract    0.7
Decrease, n (%) 70 (23.2) 67 (24.3)  
No change, n (%) 198 (65.6) 184 (66.8)  
Increase, n (%) 34 (11.3) 25 (9.1)  
IgG to MSP2    0.6
Decrease, n (%) 63 (20.9) 49 (17.8)  
No change, n (%) 217 (71.9) 203 (73.6)  
Increase, n (%) 22 (7.3) 24 (8.7)  
IgG to MSP3    0.8
Decrease, n (%) 55 (18.2) 53 (19.1)  
No change, n (%) 220 (72.8) 203 (73.3)  
Increase, n (%) 27 (8.9) 21 (7.6)  
IgG to PfRh2    0.05
Decrease, n (%) 34 (11.2) 39 (14.1)  
No change, n (%) 244 (80.5) 228 (82.3)  
Increase, n (%) 25 (8.3) 10 (3.6)  
Opsonizing IgG to E8B-ICAM    0.004
Decrease, n (%) 72 (23.9) 60 (21.7)  
No change, n (%) 140 (46.5) 164 (59.2)  
Increase, n (%) 89 (29.6) 53 (19.1)  
Opsonizing IgG to CS2    0.03
Decrease, n (%) 39 (13.0) 47 (17.0)  
No change, n (%) 226 (75.1) 180 (65.2)  
Increase, n (%) 36 (12.0) 49 (17.8)  
  1. Data represented as numbers and percentage, P-values are also shown
  2. AZ azithromycin, CQ chloroquine, SP sulfadoxine-pyrimethamine
  3. Significant associations (p < 0.05) highlighted in bold